Call Us
Everhope Logo
Colorectal Cancer
Therapy
Immunotherapy for Colorectal Cancer - Advanced Cancer Care

Immunotherapy for Colorectal Cancer - Advanced Cancer Care

Immunotherapy for Colorectal Cancer

What is Immunotherapy for Colorectal Cancer?

Immunotherapy for colorectal cancer involves medicines that help the body's immune system recognize and destroy cancer cells more effectively. This treatment primarily benefits patients whose tumors exhibit specific genetic changes such as mismatch-repair deficiency (dMMR) or high microsatellite instability (MSI-H). Immune checkpoint inhibitors—including drugs like pembrolizumab and nivolumab—restore immune response by blocking proteins that cancer cells use to evade immune attack.

Types of Immunotherapy for Colorectal Cancer

  • •Immune checkpoint inhibitors (ICIs)
    Target PD-1, PD-L1, and CTLA-4 pathways, activating immune cells. Approved ICIs include pembrolizumab, nivolumab, and ipilimumab, mostly for MSI-H/dMMR metastatic colorectal cancer.
  • •Cell therapies
    Experimental approaches expanding tumor-infiltrating lymphocytes to enhance immunity.
  • •Combination therapies
    Using ICIs with chemotherapy, radiation, or targeted agents to improve effectiveness, especially in microsatellite stable (MSS) tumors resistant to monotherapy.

When Immunotherapy is Indicated

Immunotherapy is approved for patients with advanced or metastatic colorectal cancer who have MSI-H or dMMR tumor profiles. Clinical trials are ongoing to explore its use in earlier-stage disease and combination regimens to overcome resistance in MSS tumors.

Immunotherapy Treatment Process

Immunotherapy is administered via intravenous infusion in outpatient settings, usually every few weeks. Treatment continues until disease progression or unacceptable toxicity. Generally well tolerated, but close monitoring is essential.

Benefits and Risks

Benefits of Immunotherapy for Colorectal Cancer

Durable responses and long-term remission in eligible patients

Novel mechanism differing from chemotherapy and targeted therapy

Potentially fewer side effects compared to traditional chemotherapy

Side Effects and Risks

Side effects include fatigue, rash, diarrhea, immune-related adverse events (such as inflammation of organs), and infusion-related reactions. Early recognition and management with immunosuppressants or corticosteroids is critical.

Aftercare and Recovery

Follow-up involves regular assessment of response and side effects, prompt reporting of immune-related symptoms, and supportive care to maintain quality of life.

Why Choose Everhope

Everhope Oncology offers state-of-the-art immunotherapies for colorectal cancer, including FDA-approved immune checkpoint inhibitors and clinical trial access. The program includes expert molecular profiling, personalized treatment plans, and comprehensive patient support throughout therapy.

FAQs

It activates the immune system to attack tumor cells, effective mainly in MSI-H/dMMR tumors.

Primarily immune checkpoint inhibitors and experimental cell therapies, often given with other treatments.

Costs vary by therapy type, location, and insurance; assistance programs may help.

Fatigue, rash, diarrhea, and immune-related inflammation of organs; these can be serious but manageable.

Through intravenous infusions every few weeks in outpatient clinics.

Durable responses, potential long-term remission, and a unique mode of action compared to chemo or targeted therapies.

Yes, ongoing trials explore combinations and new immune therapies to broaden benefits.

Table of Content